What Miracell does

Miracell (미라셀주식회사) is a South Korea-based stem cell specialist company that develops, manufactures, and commercializes point-of-care stem cell extraction systems, proprietary consumable kits, cell banking services, and downstream stem cell therapies. Founded in 2009 and headquartered in Seoul with an R&D center at Osong Bio Valley, the company serves approximately 650 domestic and international hospitals and clinics, an installed base that the company references alongside its stated tagline positioning as the "Standard of Stem Cell." Miracell is co-led by Shin Hyun-soon and Shin Nu-ri as co-representatives, and it operates a related branded clinic network (Cellpia) plus an e-commerce and home-shopping consumer channel for cell banking and cosmetics.

Name

Miracell

Legal name

미라셀주식회사

Website

https://miracell.co.kr

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Miracell is a Korean stem cell specialist company that develops FDA 510(k)-cleared SMART M-CELL extraction systems, proprietary kits, cell banking, and stem cell therapies for hospitals, clinics, and consumers across 13+ countries.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Cell Therapy Developers (Autologous) (HLAAABAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Stem cell extraction
• Medical devices
• Regenerative medicine
• Cell banking services
• Autologous stem cell therapy

Headquarters

HQ city

Yeoksamdong

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Devices and Consumables (SMART M-CELL Systems and Kits): Sale of SMART M-CELL and SMART M-CELL2 stem cell extraction devices along with proprietary BmSC and BSC kit consumables to hospitals and clinics. The company holds FDA 510(k) clearance and Korean regulatory approvals, enabling sales to medical institutions domestically and internationally.
2. Cell Banking (CellBanking Service): Immune cell and stem cell extraction and long-term cryopreservation service offered to individual consumers. Cells are stored for 20-30 years. Pricing is offered via rental model (monthly installments) in partnership with Barorental, making the service accessible at approximately KRW 62,000/month over 60 months.
3. Stem Cell Therapy Procedures: Stem cell treatments for various conditions including osteoarthritis, diabetic limb ischemia, myocardial infarction, Alzheimer's disease, and cosmetic applications (skin rejuvenation, hair loss) performed at partner clinics under the Cellpia brand.
4. Cosmetics (Stem Cell Culture Medium Products): Cosmetics products utilizing stem cell culture medium, sold under the Cellpia Cosmetics brand through the Miracell Mall e-commerce platform and potentially through partner retailers.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Miracell designs, manufactures, and sells FDA 510(k)-cleared SMART M-CELL closed-system stem cell extraction devices and proprietary BmSC (bone marrow) and BSC (blood) kits to hospitals and clinics for point-of-care autologous regenerative therapies. The company also provides a CellBanking cryopreservation service for individual consumers storing immune and stem cells for 20+ years, Cellpia-branded cosmetics using stem cell culture medium, and operates a Cellpia Global Platform (CGP) partner clinic network.

Product overview

Miracell operates a platform-plus-modules product architecture centered on the FDA 510(k)-cleared SMART M-CELL stem cell extraction system. The core Smart M-Cell platform uses centrifugation technology to automatically separate and concentrate stem cells from bone marrow and blood samples. Supporting modules include the BmSC Kit (bone marrow stem cell kits in 60/120/240 variants) and BSC Kit (blood stem cell kits in 30/60/120/240 variants) for different cell sources, Chroma M-CELL for cell analysis, Smart Carti 99 for orthopedic applications, Vacuum Lock Syringe, and BmSC Filter Bag as consumable components. The company also offers complementary services including CellBanking (cell extraction and cryopreservation), Stemcell Medical Platform (Starpia) for practitioner networking, and Medical AICC for hospital automation. The portfolio serves hospitals and clinics performing stem cell therapies for conditions including Alzheimer's disease, osteoarthritis, diabetic limb ischemia, and cartilage regeneration.

Differentiator

Problem solved

Functional benefit

Brands

• Cellpia: Stem cell clinic network and cosmetics brand
• Cellpia Mall
• SMART M-CELL
• BmSC Kit
• BSC Kit
• Chroma M-CELL
• Smart Carti 99
• Miracell Membership
• CellBanking
• Starpia (스타피아)
• Medical AICC

Products and services

• Smart M-Cell (SMART M-CELL / SMART M-CELL2) FDA 510(k)-cleared closed-system stem cell extraction platform that uses centrifugation to automatically separate and concentrate CD34+ hematopoietic stem cells from blood and mesenchymal stem cells from bone marrow without need for cell culture. Designed for point-of-care use at hospitals and clinics treating orthopedic, cardiovascular, neurological, and dermatological conditions.
• BmSC Kit (Bone marrow Stem Cell Kit) Specialized consumable kit for extracting mesenchymal stem cells from bone marrow using the SMART M-CELL system. Available in 60, 120, and 240 size variants for different volume requirements. Used for cartilage regeneration, diabetic severe limb ischemia, myocardial infarction, and other degenerative condition treatments.
• BSC Kit (Blood Stem Cell Kit) Specialized consumable kit for extracting CD34+ hematopoietic stem cells from peripheral blood using the SMART M-CELL system. Available in 30, 60, 120, and 240 size variants for different volume requirements. Used for blood-derived stem cell therapies including the FDA 510(k)-cleared Alzheimer's disease treatment protocol.
• Chroma M-CELL Cell analysis and sorting device used in conjunction with the SMART M-CELL stem cell extraction system for cell characterization and quality control in hospital and clinic settings.
• Vacuum Lock Syringe Specialized syringe for stem cell collection and transfer during bone marrow aspiration procedures. Designed for use with the SMART M-CELL system to maintain closed-system integrity.
• Smart Carti 99 Orthopedic treatment system for cartilage regeneration using stem cell therapy for joint applications, particularly targeting degenerative knee arthritis. Achieved 70%+ cartilage regeneration in clinical use at International Saint Mary's Hospital.
• BmSC Filter Bag Filter bag component for the BmSC Kit used in bone marrow stem cell processing and filtration as part of the SMART M-CELL extraction workflow.
• CellBanking Service Immune cell and stem cell extraction and long-term cryopreservation service for individual consumers. Cells are stored in liquid nitrogen tanks for 20-30+ years. Available via rental subscription at ~KRW 62,000/month over 60 months through Barorental partnership. Includes bundled free health check packages with DNA analysis, cell health assessment, biological age testing, and telomere testing.
• Stemcell Medical Platform (Starpia) Online community platform (스타피아) that connects stem cell treatment practitioners, enabling knowledge sharing, procedure community access, and stem cell medical service coordination among partner clinics and healthcare providers.
• Medical AICC Medical AI call center solution for hospital workflow automation and patient inquiry handling. Supports hospitals and clinics using Miracell systems with patient communication and administrative task automation.
• Miracell Membership Membership program providing access to Miracell's stem cell services and exclusive benefits including CellBanking enrollment and priority access to partner clinic treatments.

Quantifiable outcome

• Cognitive scales MMSE, CDR, and ADAS-Cog showed improvement in moderate to severe Alzheimer's patients receiving three intravenous CD34+ cell-rich autologous infusions at four-week intervals. Reduced amyloid plaque burden, increased brain glucose metabolism, and reduced hippocampal atrophy were documented vs. control group with no notable improvements.
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• SmartStempCell (스마트스템셀)coreStrategic or Co-development PartnerMiracell partnered with SmartStempCell to expand its cell banking business. SmartStempCell Banking is a 'Total Premium Cell Banking' service that separates and stores stem cells, immune cells, and growth factors from blood, bone marrow, and adipose tissue. This partnership enhanced Miracell's cell storage offerings with premium health check packages including DNA analysis, cell health assessment, biological age testing, and telomere testing.
• Yonsei University Severance Hospital (연세대학교 세브란스병원)coreStrategic or Co-development PartnerConducted landmark clinical study using SMART M-CELL-based CD34+ cell-rich autologous blood concentrate therapy for moderate to severe Alzheimer's patients. Study led by researchers at Yonsei University Severance Hospital in South Korea and published in SCIE-indexed journal Molecular Neurobiology (2026).
• Barorental (바로렌탈)coreChannel Partner/ Reseller/ DistributorPartnership with Barorental rental service company to offer cell banking membership as a rental product. Barorental developed a special financial program to make cell banking accessible to consumers at approximately KRW 62,000/month over 60 months, reducing customer cost burden.
• Ewha Womans University Medical Center (이화여자대학교 의료원)minorStrategic or Co-development PartnerMiracell (주) is one of 10 companies selected to join the Ewha Advanced Convergent Healthcare Technology Development Hub (이화 첨단 융복합 메디컬 클러스터) at Ewha Womans University Medical Center. The cluster provides research equipment access, animal lab facilities, and networking programs. Miracell signed a business cooperation agreement for clinical research collaboration and basic medical research and industrialization.
• Harvard Medical School / Harvard Medical School Immunology Research InstitutecoreTechnology or IntegrationMiracell originally licensed cell extraction technology from Harvard Medical School in 2009 and subsequently developed its own SMART M-CELL2 system as a domestic replacement for the Harvard-developed SmartPReP2 system. The company has maintained technological ties with Harvard research methodology.
• Cellpia (셀피아)coreChannel Partner/ Reseller/ DistributorCellpia is a related branded clinic network under the Miracell ecosystem. Miracell provides Cellpia clinics with stem cell technology, equipment, training, and marketing support. The Cellpia Clinic network and Cellpia Cosmetics brand represent Miracell's downstream channel ecosystem for direct-to-patient services.
• Korean Military Medical Command (국군의무사령부 / 국군병원)minorChannel Partner/ Reseller/ DistributorFollowing designation as a Public Innovation Product by the Korea Defense Procurement Agency, Miracell is in discussions with the Korean Military Medical Command to supply SMART M-CELL2 devices to military hospitals for treatment of servicemen with injuries and chronic pain conditions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ThermoGenesis Holdings: Developer of automated cell processing and cryopreservation systems (e.g., AXP, BioArchive) for clinical and commercial cell therapy applications. Closely comparable to Miracell's SMART M-CELL closed-system separation and CellBanking services, targeting similar hospitals, fertility clinics, and regenerative medicine workflows.
• Arteriocyte Medical Systems (Celling Biosciences): Developer of point-of-care autologous cell concentration systems (Magellan, ARC systems) used in orthopedic and spine surgery. Closely comparable to Miracell in BMAC device architecture, hospital-channel GTM, and regenerative orthopedic indication focus.
• Pharmicell: Korean stem cell therapy company offering autologous bone marrow-derived MSC treatments (Hearticellgram-AMI for myocardial infarction) through hospital partnerships. Comparable to Miracell in clinical indications, autologous processing workflow, and Korean hospital channel strategy.
• EmCyte Corporation: U.S. manufacturer of point-of-care autologous biologics systems (PureBMC, PurePRP) for orthopedic and regenerative applications. Direct competitor to Miracell's SMART M-CELL platform in the BMAC/concentrated stem cell device category, targeting sports medicine and orthopedic clinics.
• Cesca Therapeutics (now part of ThermoGenesis): Historical competitor in autologous cell therapy devices (formerly developed the SurgWerks and ThermoGenesis platforms for point-of-care cell processing). Comparable to Miracell in clinical workflow and indications, though focused primarily on cardiovascular and critical limb ischemia.
• Medipost: Korean stem cell therapeutics company that developed Cartistem (allogeneic umbilical cord blood-derived MSC therapy for cartilage regeneration). Direct Korean-domestic peer in stem cell medicine with overlapping clinical indications (orthopedics, neurodegenerative) and a similar hospital-channel GTM.

Regional players

• RNL Bio (R Bio): Korean stem cell therapy company with autologous adipose-derived stem cell banking and clinical applications. Comparable to Miracell in Korean-market cell banking and autologous stem cell treatment services, though with a different tissue source (adipose vs. blood/bone marrow).
• Histogenics (now Ocugen) / Israeli Cell Therapy: Cell therapy developers focused on regenerative medicine for orthopedic applications (Neocart scaffold-based cartilage repair). Comparable in cartilage regeneration indication and autologous cell processing, though operating in different geographies.

Broad incumbents

• Mesoblast: Global mesenchymal stem cell therapy developer (remestemcel-L for pediatric SR-aGvHD, advanced heart failure programs). Comparable in therapeutic indication breadth (cardiovascular, orthopedic, inflammatory) and clinical-stage regenerative medicine focus, though operating as a pharmaceutical-style developer rather than device company.
• Vericel Corporation: U.S. commercial-stage cell therapy company (MACI cartilage repair, Epicel burn grafts) operating a vertically integrated autologous cell therapy model. Comparable in clinical cell therapy development and commercialization, though at significantly greater scale and U.S. regulatory depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/miracellco

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miracell